PhaseBio touts 'breakthrough' badge for bloodthinner reversal agent licensed from AstraZeneca, shares leap
At PhaseBio, the game plan has been to hustle its Brilinta reversal agent, PB2452, down what it sees as a short path to approval, unlocking …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
